8-K: Blueprint Medicines Sells U.S. Rights to Gavreto, Ends Roche Collaboration

Blueprint Medicines has sold the U.S. rights to its cancer drug Gavreto to Rigel Pharmaceuticals for $15 million upfront, plus potential milestones and royalties, and terminated its global collaboration with Roche for the same drug.

Summary

• Blueprint Medicines has entered into an agreement to sell the U.S. rights to Gavreto (pralsetinib) to Rigel Pharmaceuticals for an initial payment of $15 million.
• The $15 million payment includes $10 million upon the first commercial sale by Rigel and an additional $5 million one year after closing, subject to transition activities.
• Blueprint Medicines is also eligible for up to $102.5 million in regulatory and commercial milestone payments, plus tiered royalties from 10% to 30%.
• The transition of Gavreto to Rigel is expected to be completed in the third quarter of 2024.
• The company has also terminated its global collaboration with Roche for Gavreto, excluding Greater China.
• This termination follows a previously announced plan to discontinue global development and marketing of Gavreto outside the U.S. and Greater China.
• A related agreement with Royalty Pharma to sell royalties from the Roche collaboration has also been terminated.
• Blueprint Medicines anticipates significantly lower operating expenses related to Gavreto due to the wind-down of the Roche collaboration, with no material impact on overall 2024 operating expense plans.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is giving up U.S. rights to a drug, it is receiving upfront cash, potential future payments, and reducing operating expenses. The strategic shift is expected, but the long-term impact is uncertain.

Positives

• The sale of U.S. rights to Gavreto provides Blueprint Medicines with an immediate cash infusion of $15 million.
• The potential for up to $102.5 million in milestone payments and tiered royalties offers additional revenue opportunities.
• The termination of the Roche collaboration is expected to significantly reduce operating expenses related to Gavreto.
• The company expects no material impact to its overall operating expense plans in 2024 despite the changes.

Negatives

• The company is giving up U.S. rights to a currently approved drug, which could limit future revenue potential.
• The termination of the Roche collaboration means Blueprint Medicines will no longer receive revenue from global sales of Gavreto outside of Greater China.
• The company is relying on Rigel's ability to successfully commercialize Gavreto in the U.S. to realize milestone payments and royalties.

Risks

• The success of the deal is dependent on Rigel's ability to successfully commercialize Gavreto in the U.S.
• The company may not receive the full $102.5 million in milestone payments if Rigel does not achieve certain regulatory and commercial targets.
• The transition of Gavreto to Rigel could face unforeseen challenges, potentially delaying the receipt of payments.
• The termination of the Roche collaboration could impact the long-term revenue potential of Gavreto.

Future Outlook

Blueprint Medicines expects significantly lower year-over-year operating expenses related to Gavreto and no material impact to the company's overall operating expense plans in 2024.

Management Comments

• The company expects the wind-down of the Roche Collaboration for GAVRETO will result in significantly lower year-over-year operating expenses related to GAVRETO.
• The company expects no material impact to the company's overall operating expense plans in 2024.

Industry Context

This announcement reflects a trend of pharmaceutical companies focusing on core assets and divesting non-core products. The sale of Gavreto rights allows Blueprint Medicines to streamline operations and potentially focus on other pipeline candidates. The deal also highlights the ongoing consolidation and strategic partnerships within the pharmaceutical industry.

Comparison to Industry Standards

• The deal structure, with an upfront payment, milestone payments, and royalties, is a common practice in the pharmaceutical industry for asset sales.
• Similar deals include the sale of development rights for various drugs, often involving smaller companies acquiring assets from larger ones to focus on specific therapeutic areas.
• The royalty rates of 10% to 30% are within the typical range for pharmaceutical product royalties, although the specific rate depends on the stage of development and market potential of the drug.
• The termination of the Roche collaboration is not uncommon, as companies often reassess their partnerships based on strategic priorities and market conditions.

Stakeholder Impact

• Shareholders may view the sale of Gavreto rights as a strategic move to streamline operations and focus on core assets.
• Employees involved in the Gavreto program may be affected by the transition to Rigel Pharmaceuticals.
• Patients in the U.S. will continue to have access to Gavreto through Rigel Pharmaceuticals.
• Roche will no longer be involved in the development and commercialization of Gavreto outside of Greater China.

Next Steps

• The transition of Gavreto to Rigel Pharmaceuticals is expected to be completed in the third quarter of 2024.
• Blueprint Medicines will focus on other pipeline candidates and strategic priorities.

Key Dates

Keywords

Gavreto, pralsetinib, Rigel Pharmaceuticals, Roche, Royalty Pharma, asset sale, collaboration, milestone payments, royalties, cancer drug, RET inhibitor